Navigation Links
Zevacor Molecular to Open Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
Date:9/25/2013

INDIANAPOLIS, Sept. 25, 2013 /PRNewswire/ -- The Zevacor Molecular Board of Directors announced approval of funding to purchase the only 70 MeV commercial cyclotron dedicated to medical use in the United States. Zevacor Molecular is engaged with various vendors and will award the contract within 30 days. The 70 MeV cyclotron, expected to be operational in the fall of 2016, will expand Zevacor Molecular's pharmaceutical line.

Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has committed to this multi-million dollar project to introduce a commercial medical 70 MeV Cyclotron in order to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses.

"Medical isotopes are critical to early and accurate diagnosis of cancer, heart disease and a number of other life threatening diseases," said Zevacor Molecular Executive Vice President and Chief Operating Officer John Zehner. "In the past, the supply of medical isotopes has not been continuous, making it difficult to offer these diagnostics and therapeutics. This investment will allow us to provide year round production of medically necessary isotopes for patients."

Zevacor Molecular was established in 2012. Zevacor's efforts come at a time when there is little certainty of supply in the market for medical isotopes. The 70 MeV will have the ability to supply patients with medically necessary isotopes used for diagnostic imaging and therapies within oncology, neurology and cardiology. Although the project is focused on Strontium (Sr-82), which is the raw material for Rubidium (Rb-82) generators, it also opens up several research isotopes currently not widely available in the United States such as Copper-67 which is a therapeutic for treating cancer.


'/>"/>
SOURCE Zevacor Molecular
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
5. The 2012 US Molecular Diagnostics Market
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
8. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
9. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
10. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
11. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey ... to residential and commercial clients in the northern Alabama and Georgia regions, is ... , Since 1977, Nobis Works has built a network of support and education ...
Breaking Medicine News(10 mins):